Business
Faron to Present at H.C. Wainwright
Faron to Present at H.C. Wainwright.
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"\n \n \n \n RNS Number : 3089K\n Faron Pharmaceuticals Oy\n 04 January 2021\n \n \n \n \n \n Faron Pharmaceuticals \n \n \n Oy\n \n \n \n (\"Faron\" or the \"Company\")\n \n \n \n \n \n Faron to Present at H.C. Wainwright BioConnect \n \n \n \n \n \n \n TURKU - FINLAND, January 4, 2021 \n \n - Faron Pharmaceuticals Ltd (\n \"\n Faron\") (LON: FARN), \n the clinical stage biopharmaceutical company\n , today announced that Dr. Markku Jalkanen, Chief Executive Officer of Faron Pharmaceuticals, will present in a pre-recorded presentation at the virtual H.C. Wainwright BioConnect Conference that will be available on-demand starting Monday, January 11, 2021 at 6:00 a.m. ET.\n \n \n \n \n \n An audio webcast of the presentations will be available in the \n \"Investors\" section on Faron's website at \n \n https://www.faron.com/investors\n \n \n \n \n \n \n \n ENDS\n \n \n \n \n \n \n \n \n For more information please contact:\n \n \n \n \n \n Stern Investor Relations, Inc.\n \n \n Julie Seidel, Naina Zaman\n \n \n Phone: +(1)212 362 1200\n \n \n Email: \n \n \n [email protected]\n \n \n \n \n \n \n \n \n Consilium Strategic Communications\n \n \n Mary-Jane Elliott, David Daley, Lindsey Neville\n \n \n Phone: +44 (0)20 3709 5700\n \n \n E-mail: \n \n \n [email protected]\n \n \n \n \n \n \n \n About Faron Pharmaceuticals Ltd \n \n \n Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. Currently in phase I/II clinical development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, Clevegen has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine, the Company's pipeline candidate to prevent vascular leakage and organ failures is currentl...